A combination therapy for treating cancer showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results presented from a double-blind, placebo-controlled phase 2 trial.
A combination therapy for treating cancer showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results presented from a double-blind, placebo-controlled phase 2 trial.